We then performed two-sample MR (2SMR) and Bayesian colocalization analyses to further estimate the causal effect of GLP-1Rs dual- and tri-peptidic agonists on MASLD, its metabolic risk factors, and multiple-organ complications
#GLP1 #Noom #ObesityTreatment #DigitalHealth #WeightLoss #Semaglutide #HealthTech #CompoundedDrugs #PharmaInnovation #BehavioralHealth To view or add a comment, sign in More Relevant Posts #MIMSPharmaMarketInsightUpdate, September 2025 Including: SGLT2 inhibitors should be offered first-line to people with heart failure with reduced ejection fraction A new formulation of Rybelsus (semaglutide) tablets has been released The first inhaled levodopa product, Inbrija (levodopa), has been launched
57% of EU liver specialists surveyed by Ipsos in Q1 25 (prior to approval in August) expected diagnoses to rise with an approved GLP1
The evidence is extremely limited
Like all GLP-1 medications, GLP-1 works best over time and alongside healthy habits
Tirzepatide (brand names Mounjaro and Zepbound) resulted in a decrease in 10.1 percent of body weight at six months and semaglutide (brand names Ozempic, Wegovy, and Rybelsus) resulted in a decrease of 5.8 percent of body weight at six months, according to a 2024 study in JAMA Internal Medicine